TGFB1 and vitreoretinal degeneration: Since TGF-β is involved in mTOR signaling and mTORC1 inhibitor-rapamycin plays a significant role in anti-proliferative properties, it will be interesting to see if rapamycin can be used for treatment purposes in vitreoretinopathy [68].